Abstract: Provided is a method of setting criteria for classification of data in an electronic apparatus, the method including identifying a subtask related to data classification, obtaining a plurality of data, based on a model associated with the subtask, obtaining a score associated with the subtask for each of the plurality of data, identifying category information associated with the subtask for each of the plurality of data, and based on the category information and the score, determining a threshold value corresponding to the subtask.

Abstract: The present disclosure relates to novel chlorine e6-curcumin derivatives, a preparation method thereof for the treatment of cancer, and in particularly, novel compounds were prepared by using different linkers such as hydrophobic and hydrophilic linkers to conjugate chlorine e6 to curcumin, the compounds under investigation showed excellent photophysical properties, stability, and anticancer activity.

Abstract: The present invention relates to a mannanase produced from Celluosimicrobium sp. strain HY-13 and more particularly to a highly active novel mannanase produced from Cellulosimicrobium sp. strain HY-13 as separated from an invertebrate. The mannanase produced from the said Cellulosimicrobium sp. strain HY-13 can be used in the decomposition of a mannan found in hemicellulose contained in grains and plants and in enhancing the utility value of a hydrolysate, which uses the decomposed mannan, for the transformation of biomass or as an animal feed material.

Abstract: The present invention relates to novel iturin biosynthesis genes, and uses thereof. More specifically, the present invention provides novel iturin biosynthesis genes, wherein the iturin biosynthesis genes were cloned from Bacillus subtilis subsp. krictiensis ATCC 55079, the base sequence was determined after checking whether the cloned genes are iturin biosynthesis genes or not, and it was ascertained that the identified genes are novel genes different from the reported gene by comparing the base sequences with that of the reported gene, and uses thereof.

Abstract: The present invention relates to a mannanase produced from Celluosimicrobium sp. strain HY-13 and more particularly to a highly active novel mannanase produced from Cellulosimicrobium sp. strain HY-13 as separated from an invertebrate. The mannanase produced from the said Cellulosimicrobium ap. strain HY-13 can be used in the decomposition of a mannan found in hemicellulose contained in grains and plants and in enhancing the utility value of a hydrolysate, which uses the decomposed mannan, for the transformation of biomass or as an animal feed material.

Abstract: The present invention relates to novel iturin biosynthesis genes, and uses thereof. More specifically, the present invention provides novel iturin biosynthesis genes, wherein the iturin biosynthesis genes were cloned from Bacillus subtilis subsp. krictiensis ATCC 55079, the base sequence was determined after checking whether the cloned genes are iturin biosynthesis genes or not, and it was ascertained that the identified genes are novel genes different from the reported gene by comparing the base sequences with that of the reported gene, and uses thereof.

Abstract: The invention provides a method for treating lung cancer or breast cancer wherein the method comprises administering a pharmaceutically effective dose of arazyme enzyme to a subject with lung cancer or breast cancer. The arazyme enzyme is either a protein comprising the amino acid sequence of SEQ ID NO: 1; and/or a protein encoded by DNA comprising the coding region of the nucleotide sequence of SEQ ID NO: 2.

Abstract: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis.

Abstract: The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.

Abstract: There are provided a novel xylanase and a use of the same. In detail, there are provided a xylanase separated from a Cellulosimicrobium funkei HY-13 strain, a Fibronectin Type 3 domain of the xylanase, and a use thereof. Since determining that the xylanase having substrate specificity degrades xylan at neutral and basic pH with high efficiency and the Fn3 domain does an important role with respect to the substrate specificity, the xylanase according to the present invention may be added to various vegetable feed materials or be efficiently used to improve degradation ability of cellulosic biomass.

Abstract: The present invention relates to obovatol compound isolated from Magnolia obovata Thunb. for the prevention and treatment of anxiety disorders involved with CNS. The obovatol compound isolated from Magnolia obovata Thunb. have potent anti-anxiety activity, verified by an increased percentage of time on the open arms, an increased number of entries into, time spent on, the distal portion of the open arms, and a decreased activity of locomotor. Therefore it can be used as the therapeutics or health care food for treating and preventing anxiety disorders.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-?B and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

Abstract: Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from Aranicola proteolyticus of the present invention may be useful as a composition for prevention and treatment of arthritis by inhibiting the expression of TNF-? which is an inflammation-inducing factor and preventing the loss of proteoglycan and collagen from joint cartilage to inhibit the progression of arthritis and protect joints.

Abstract: Disclosed herein is an agent for preventing and treating cancer which includes an oxadiazole urea compound represented by Chemical Formula 1, below, as an effective ingredient. The oxadiazole urea compound effectively inhibits the growth of cancer cell lines and the activity of STAT3, and may be used in the prevention and treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-?B and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

Abstract: The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy.

Abstract: The present invention relates to a protease, and more specifically to a protease derived from Aranicola proteolyticus, a gene coding for said enzyme, a gene expression system for said protease, a process for purifying the protease, and the uses of said protease in industrial applications, such as for example, detergents, cosmetics, leather processing agents, chemicals for laboratory research, solubilizing or softening agents for food, meat modifier, feed or food additives, or oil and fat separating agents, as well as pharmaceutical compositions.

Abstract: Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis.